The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Takeda will seek an external partner to leverage its cell therapy platform technologies
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Upgrades 2025 full-year CDMO sales and margin outlook
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
